Anatomy of an Epidemic

The Long-Term Effects of Psychiatric Medications on Affective Disorders

Robert Whitaker
April 2013
A Global Epidemic

Over the past 25 years, the number of people disabled by mental illness has soared in societies that have embraced the use of antidepressants and other psychiatric drugs.
U.S. Disability in the Prozac Era

Millions of adults, 18 to 66 years old

Source: U.S. Social Security Administration Reports, 1987-2010
Disability Due to Psychiatric Disorders in Australia, 1990-2011

Disability Due to Psychiatric Disorders in New Zealand, 1998-2011

Disability Due to Mental and Behavioural Disorders in Iceland, 1990-2007

Number of New Cases Annually per 100,000 Population

New Cases of Disability in Denmark Due to Mental Illness

The Question Raised by the Disability Data:

How do psychiatric medications affect the long-term course of mental disorders? Do they increase the likelihood that people diagnosed with a major mental disorder will do well over the long-term? Or do they increase the likelihood that people so diagnosed will have a poor long-term outcome?
Is Depression Due to A Chemical Imbalance in the Brain?
“Elevations or decrements in the functioning of serotonergic systems per se are not likely to be associated with depression.”

“There is no clear and convincing evidence that monoamine deficiency accounts for depression; that is, there is no real monamine deficit.”

“After more than a decade of PET studies, monamine depletion studies, and genetic association analyses examining polymorphisms in monaminergic genes, there is little evidence to implicate true deficits in serotonergic, noradrenergic, or dopaminergic neurotransmission in the pathophysiology of depression. This is not surprising, as there is no a priori reason that the mechanism of action of a treatment is the opposite of disease pathophysiology.”

Stephen Hyman, former director of the NIMH, 1996:

- Psychiatric medications “create perturbations in neurotransmitter functions.”

- In response, the brain goes through a series of compensatory adaptations in order “to maintain their equilibrium in the face of alterations in the environment or changes in the internal milieu.”

- The “chronic administration” of the drugs then cause “substantial and long-lasting alterations in neural function.”

- After a few weeks, the person’s brain is now functioning in a manner that is “qualitatively as well as quantitatively different from the normal state.”

What Compensatory Adaptations Are Triggered by An SSRI?

• There is a decrease in the release of serotonin by presynaptic neurons, at least for a period of time. (In rat studies, serotonin eventually becomes depleted in the forebrain.)

• The postsynaptic neurons decrease the density of receptors for serotonin, an adaptive process known as “downregulation” of receptors.

• Thus, the compensatory adaptions drive the brain into a subsensitive serotonergic state over the long term.
Depression in the Pre-Antidepressant Era
Who It Affected

Major depression was primarily a disorder of middle-aged and older persons. In 1956, 90% of first admissions to public and private hospitals in the United States for depression were 35 years and older.

Prevalence

In the 1930s and 1940s, fewer than one in a thousand adults suffered an episode of clinical depression each year. (In U.S.)

Hospitalization

In 1955, there were only 7,250 “first admissions” for depression in state and county mental hospitals in the U.S. the total number of depressed patients in the nation’s mental hospitals that year was 38,200.
Short-term Outcomes in the Pre-Antidepressant Era

The depressive symptoms could be expected to lift, although it could take six months or more.

“Depression is, on the whole, one of the psychiatric conditions with the best prognosis for eventual recovery with or without treatment. Most depressions are self-limited.” --Jonathan Cole, NIMH, 1964.

“In the treatment of depression, one always has an ally the fact that most depressions terminate in spontaneous remissions. This means that in many cases regardless of what one does the patient eventually will begin to get better.” --Nathan Kline, Journal of the American Medical Association, 1964

Most depressive episodes “will run their course and terminate with virtually complete recovery without specific intervention.” -- Dean Schuyler, head of the depression section at the NIMH, 1974
Long-term outcomes in the Pre-Antidepressant Era

• Emil Kraepelin, 1921. Sixty percent of 450 patients hospitalized for an initial bout of depression experienced but a single bout of the illness, and only 13% had three or more episodes in their lives.

• Horatio Pollock, New York State, 1931. In a long-term study of 2700 first-episode depressed patients, more than half never had another bout of depression, and only 13% had three or more episodes.

• Gunnar Lundquist, Sweden, 1945. In an 18-year study of 216 patients, 49% had only a single episode, and another 21% had only one other episode.
“Assurance can be given to a patient and to his family that subsequent episodes of illness after a first mania or even a first depression will not tend toward a more chronic course.”

--George Winokur, Washington University, Manic Depressive Illness, 1969
Conclusion:

Prior to the antidepressant era, clinical depression was primarily a disorder that affected older people and was fairly uncommon. Most of those affected could expect to recover from a depressive episode within 12 months (80% or so), and over the long-term, depression ran an episodic course. Half of first episode patients would never experience another episode severe enough to require rehospitalization, and only 20% or so would become chronically ill.
The Efficacy of SSRIs Over the Short Term
The National Institute of Clinical Excellence in Britain determined that a three-point difference was needed on the Hamilton scale to demonstrate a “clinically significant benefit.” Difference here is 1.8 points.

Efficacy of Four SSRIs According to Severity of Illness

Drug-Placebo Difference on HDRS

Moderate: 14-18
Severe: 19-22
Very Severe: 23-27
Extremely Severe: 28 plus

HDRS Baseline Scores

“Given these data there seems little evidence to support prescription of antidepressants to even the most severely depressed patients unless alternative treatments have failed to provide benefit.

--Irving Kirsch
Meta-analysis of Trials Without Placebo Washout Design

• In patients with HRSD baseline score less than 25: “Drug/placebo differences did not meet either of the 2 thresholds for clinical significance proposed by NICE.”

• In patients with HRSD baseline scores above 25: Antidepressant medication “was markedly superior to placebo.”

“Efforts should be made to clarify to clinicians and prospective patients that….there is little evidence to suggest that [antidepressants] produce specific pharmacological benefit for the majority of patients with less severe acute depressions.”

--Jay Fournier
Because of these findings, the National Institute of Clinical Excellence in Britain does not recommend the prescribing of antidepressants as a first-line therapy for mild to moderate depression.
The Long-term Effects of Antidepressants on Depression
The Hippocratic Oath

In order for a treatment to do no harm, it must improve on natural recovery rates.
Clinical Perceptions in Early Years of Antidepressant Use

- H.P. Hoheisel, German physician, 1966: Exposure to antidepressants appeared to be “shortening the intervals” between depressive episodes.

- Nikola Schipkowensky, Bulgarian psychiatrist, 1970: The antidepressants were inducing “a change to a more chronic course.”

The Chronicity Worry is Tested

J.D. Van Scheyen, Dutch psychiatry, 1973:

After conducting a study of 94 depressed patients, he concluded that “it was evident, particularly in the female patients, that more systematic long-term antidepressant medication, with or without ECT [electronconvulsive therapy], exerts a paradoxical effect on the recurrent nature of the vital depression. In other words, this therapeutic approach was associated with an increase in recurrent rate and a decrease in cycle duration . . . Should [this increase] be regarded as an untoward long-term side effect of treatment with tricyclic antidepressants?”
High-Relapse Rates Following Antidepressant Use

In a 1997 meta-analysis, Harvard researchers report that 50% of all drug-withdrawn patients relapsed within 14 months. They also noted that the longer the patient had been on an antidepressant prior to drug withdrawal, the higher the relapse rate.

(In the pre-antidepressant era, this was the relapse rate seen in studies that lasted 15 years or more.)

NIMH Trial in 1980s

Four Arms:

- Two forms of psychotherapy
- Tricyclic (imipramine)
- Placebo

16-Week Results

“No significant differences among treatments, including placebo plus clinical management, for the less severely and functionally impaired patients.” Only the severely depressed patients fared better on imipramine.

18-Month Results

Stay-well rate highest for psychotherapy groups (30%) and lowest for imipramine group (19%).

Further analysis of results:

If study dropouts were included in the analysis, then the results for the imipramine patients “look even worse ... patients receiving the antidepressant were most likely to seek treatment following termination, produced the highest probability of relapse, and exhibited the fewest weeks of reduced or minimal symptoms during the follow-up period.”

An Episodic Illness Turns Chronic in the Antidepressant Era

National Institute of Mental Health Panel on mood disorders, 1985:

“Improved approaches to the description and classification of [mood] disorders and new epidemiologic studies [have] demonstrated the recurrent and chronic nature of these illnesses, and the extent to which they represent a continual source of distress and dysfunction for affected individuals.”
The APA Acknowledges Change in Course of Depression in Modern Era

American Psychiatric Association’s Textbook of Psychiatry, 1999:

It used to be believed that “most patients would eventually recover from a major depressive episode. However, more extensive studies have disproved this assumption.” It was now known that “depression is a highly recurrent and pernicious disorder.”
The STAR*D Trial Confirms That Depression Runs a Chronic Course Today

Findings from the National Institute of Mental Health’s STAR*D study, which was the “largest study” of depression ever conducted:

• 38% of the patients properly enrolled in the trial and assessed according to the Hamilton Rating Scale of Depression remitted during one of the four stages of drug treatment.

• Only seven percent of the patients who remitted stayed well and in the trial during the 12-month followup. (108 of 1,518). The remaining 93% relapsed or dropped out.

• The bottom line: Of the 4,041 patients who entered the trial, only 3% remitted and then stayed well throughout the 12-month followup (108 of 4,041.) The remaining patients either failed to remit, relapsed during the followup, or dropped out.

Outcomes in Real-World Patients

In a 2004, NIMH-funded study:

• 126 patients were treated with antidepressants and given emotional and clinical support “specifically designed to maximize clinical outcomes.”

• Only 26% responded to antidepressants (50% reduction in symptoms).

• Only half of those who responded stayed better for a significant period of time.

• Only 6% remitted and then remained in remission at the end of one year.

“These findings reveal remarkably low response and remission rates.”

--John Rush, 2004
Outcomes in Minnesota

In 2009, only 1,131 of 23,887 patients treated for major depression or dysthymia were in remission at the end of one year.

Source: MN Community Measures, 2010 Health Care Quality Report
The Course of Medicated Depression Today

According to mainstream texts:

• One-third of all unipolar patients are non-responders to antidepressants. This group goes on to have a chronic course.

• Another third are partial responders. However, “resolution of major depressive episode with residual subthreshold depressive symptoms, even the first lifetime episode, appears to be the first step of a more severe, relapsing, and chronic future course.”

• The final third of patients see their symptoms remit over the short term. About half of this group, when maintained on an antidepressant, stay well for long periods of time.
“Only 15% of people with unipolar depression experience a single bout of the illness,” and for the remaining 85%, with each new episode, remissions become “less complete and new recurrences develop with less provocation.”

--American Psychiatric Association Textbook, 1999
Are Antidepressants Depressogenic Over the Long-Term?

“Antidepressant drugs in depression might be beneficial in the short term, but worsen the progression of the disease in the long term, by increasing the biochemical vulnerability to depression . . . Use of antidepressant drugs may propel the illness to a more malignant and treatment unresponsive course.”

--Giovanni Fava, *Psychotherapy and Psychosomatics*, 1995
Depression in the Netherlands
(Over the course of ten years)

- First episode treated with drug
- First episode treated without drug

Five-Year Outcomes in Canada

Number of Weeks Depressed Each Year

<table>
<thead>
<tr>
<th>On Medication</th>
<th>Off Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>11</td>
</tr>
</tbody>
</table>

N = 9,508

These findings are consistent with Giovanni Fava’s hypothesis that “antidepressant treatment may lead to a deterioration in the long-term course of mood disorders.”

--Scott Patten
One-Year Outcomes in WHO Screening Study for Depression

This “study does not support the view that failure to recognize depression has serious adverse consequences.”

--D. Goldberg
Canadian Study of Risk of Long-term Disability for Depressed Workers

“Does the lack of antidepressant use reflect a resistance to adopting a sick role and consequently a more rapid return to work?”

--Carolyn Dewa
NIMH’s Study of Untreated Depression

“The untreated individuals described here had milder and shorter-lived illnesses [than those who were treated], and, despite the absence of treatment, did not show significant changes in socioeconomic status.”

--William Coryell
One-Year Recovery Rates in NIMH-Funded Study of Unmedicated Depression

“If as many as 85% of depressed individuals who go without somatic treatment spontaneously recover within one year, it would be extremely difficult for any intervention to demonstrate a superior result to this.”

--Michael Posternak
Antidepressants Lessen the Long-Term Benefits of Exercise

<table>
<thead>
<tr>
<th>Treatment during first 16 weeks</th>
<th>Percentage of patients in remission at end of 16 weeks</th>
<th>Percentage of patients who relapsed in following six months</th>
<th>Percentage of all patients depressed at end of ten months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zoloft alone</td>
<td>69%</td>
<td>38%</td>
<td>52%</td>
</tr>
<tr>
<td>Zoloft plus exercise</td>
<td>66%</td>
<td>31%</td>
<td>55%</td>
</tr>
<tr>
<td>Exercise alone</td>
<td>60%</td>
<td>8%</td>
<td>30%</td>
</tr>
</tbody>
</table>

A Biological Explanation for Why Antidepressants May Be Depressogenic Agents Over the Long-Term

The Problem

• Over time, antidepressants induce brain changes that “are the opposite of what the medication originally produced.” Rather than raise serotonin levels, the drugs over the long-term impair serotonergic pathways in the brain.

Animal Evidence

• In studies with rats, long-term treatment with an SSRI led to markedly reduced serotonin in “nine areas of the brain.” In addition, treatment with an SSRI leads to a reduced density of receptors for serotonin in the brain.

• In experiments with animals, such impairments in serotonergic functions are “associated with increased depressive and anxious behaviors.”

“When we prolong treatment over 6-9 months, we may recruit processes that oppose the initial acute effects of antidepressant drugs (loss of clinical effects) … We may also propel the illness to a malignant and treatment-unresponsive course that may take the form of resistance or episode acceleration. When drug treatment ends, these processes may be unopposed and yield withdrawal symptoms and increased vulnerability to relapse. Such processes are not necessarily reversible.”

Giovanni Fava, 2011

Three-Month Risk of Relapse After Initial Remission: Placebo vs. SSRI-Withdrawn Patients

“The more antidepressants perturb monamine levels in the brain, the more the brain appears to push back, which increases the risk of relapse when the drug is discontinued . . . antidepressant use appears to increase [biological] susceptibility to depression.”

--Paul Andrews, 2012
Two-Year Relapse Rates for Remitted Patients in the Netherlands

“Continued antidepressant treatment may oppose the initial acute effects of [the] antidepressant . . . neurobiological mechanism(s) may be involved in increasing vulnerability” to relapse.

--C. Bockting, 2008
Summing up the Evidence That Antidepressants Are Depressogenic Over the Long Term

• Depression has changed from an episodic illness to a chronic one during the antidepressant era.

• In naturalistic studies, the unmedicated patients have better long-term outcomes.

• Investigators have proposed a biological explanation for why antidepressants are depressogenic over the long term.
Tardive Dysphoria

“A chronic and treatment-resistant depressive state is proposed to occur in individuals who are exposed to potent antagonists of serotonin reuptake pumps (i.e. SSRIs) for prolonged time periods. Due to the delay in the onset of this chronic depressive state, it is labeled tardive dysphoria. Tardive dysphoria manifests as a chronic dysphoric state that is initially transiently relieved by -- but ultimately becomes unresponsive to -- antidepressant medication. Serotonergic antidepressants may be of particular importance in the development of tardive dysphoria.”

-- Rif El-Mallakh, 2011

Other Adverse Effects of SSRIs

On Mood
- Emotional blunting, apathy
- Mania
- Conversion to bipolar

Neurocognitive Effects
- Mild cognitive impairment
- Driving accidents
- Neuronal structural damage

Gastrointestinal Effects
- Diarrhea
- Constipation
- Upset stomach

Vascular Effects
- Gastrointestinal bleeding

Movement
- Tics
- Fatigue
- Tardive dyskinesia

Sleep
- Suppression of REM sleep

Reproductive Functioning
- Sexual dysfunction

Fetal Development
- Congenital abnormalities
- Preterm births
The Burden of Depression on Society Today

In the United States

- Major depressive disorder is now the leading cause of disability in the United States for people ages 15 to 44.

- According to the NIMH, it affects 15 million American adults. Researchers at Johns Hopkins School of Public Health reported in 2008 that 58% of this group is “severely impaired.”

- Nearly nine million adults are now disabled, to some extent, by this condition.

Globally

- According to the World Health Organization, depression is now the leading cause of disability worldwide.
The Bipolar Boom

Annual Prevalence in the Pre-Lithium Era

• One in 3000 to one in 10,000

Prevalence Today:

• One in 50 adults
Gateways to Bipolar Today

• Illicit drugs (marijuana, cocaine, hallucinogens, etc.)

• Stimulants and antidepressants

• Expanded Diagnostics
The Antidepressant Pathway

In 2004, Yale University investigators reviewed the records of 87,290 patients diagnosed with depression or anxiety between 1997 and 2001, and those treated with an antidepressant converted to bipolar at the rate of 7.7% per year, which was three times greater than those not exposed to the drugs. As a result, 20 to 40% of unipolar depressed patients in the U.S. who stay on antidepressants long-term convert to bipolar illness.

Fred Goodwin, former director of the National Institute of Mental Health, 2005:

“If you create iatrogenically a bipolar patient, that patient is likely to have recurrences of bipolar illness even if the offending antidepressant is discontinued. The evidence shows that once a patient has had a manic episode, he or she is more likely to have another one, even without the antidepressant stimulation.”
In a survey of members of the Depressive and Manic-Depressive Association, 60 percent of those with a bipolar diagnosis had initially fallen ill with major depression and had turned bipolar after exposure to an antidepressant.

Bipolar Outcomes in the Pre-Drug Era

Swedish Study, 1945

103 manic patients

- 50% Recovered Patients
- 40% Chronically ill
- 20% One episode
- 10% Two or more episodes
- 0% No subsequent episodes

Outcomes for 100 manic patients first hospitalized in U.S., 1935-1945, and followed for 30 to 40 years. A good rating for each category meant that the patient was married or widowed, owned home or lived with family members, was employed or had retired, and had no psychiatric symptoms. Seventy percent of the patients had good functional outcomes, and half were asymptomatic. Source: Tsuang, M. “Long-term outcome of major psychoses.” Arch Gen Psych 36 (1979):1295-1301.
Summary of Outcomes in Pre-Drug Era

There is “no basis to consider that manic depressive psychosis permanently affected those who suffered from it. In this way, it is of course different from schizophrenia.” While some people suffered multiple episodes, each episode was usually only a “few months in duration” and “in a significant number of patients, only one episode of illness occurs.” Once patients recovered, they usually had “no difficulty resuming their usual occupations.”

--George Winokur, Washington University, 1969
Manic Depressive Illness
Worsening Long-term Course of Bipolar Illness in Drug Era

“The general impression of clinicians today is that the course of recurrences of manic-depressive illness has substantially changed in the last 20 years. The recurrences of many patients have become more frequent. One sees more manias and hypomanias . . . more rapid cyclers and more chronic depressions.”

--Anthansious Koukoulos, 1983
The Modern Course of Bipolar Illness

• More recurrent episodes and more rapid cycling

• Low-level depression between episodes

• Only 33% enjoy good functional outcomes (compared to 70% to 85% in pre-drug era)

• Long-term cognitive impairment (which wasn’t seen in pre-drug era)

• Physical problems related to long-term medication use

• Risk of early death
“It is now well established that bipolar disorders are chronic, with a course characterized by frequent affective episode recurrence.”

--Lewis Judd, 2008
Experts Recognize the Decline in Bipolar Outcomes

Carlos Zarate, head of NIMH Mood Disorders Program, 2000:

“In the era prior to pharmacotherapy, poor outcome in mania was considered a relatively rare occurrence. However, modern outcome studies have found that a majority of bipolar patients evidence high rates of functional impairment.”


“Prognosis for bipolar disorder was once considered relatively favorable, but contemporary findings suggest that disability and poor outcomes are prevalent, despite major therapeutic advances.”

Fred Goodwin, 2008

“The illness has been altered. Today we have a lot more rapid cycling than we described in the first edition [of his book, Manic Depressive Illness], a lot more mixed states than we described in the first edition, a lot more lithium resistance, and a lot more lithium treatment failure than we described in the first edition. The illness is not what Kraepelin described.”
Martin Harrow's 15-Year Study: Outcomes for Manic-Depressive Group

The Burden of Bipolar Illness on Society Today

• In 1955, there were 12,750 adults hospitalized with bipolar illness in the United States. Today there are nearly six million adults in the United States with this diagnosis.

• According to the Johns Hopkins School of Public Health, 83 percent of people diagnosed with bipolar are “severely impaired” in some facet of their lives. (5 million adults.)

• Bipolar illness is now said to be the sixth leading cause of medical-related disability in the world.
A Failed Paradigm of Care

“The time has now come to call an end to the psychopharmacological revolution of 1952 . . . all revolutions have to come to an end, and the psychopharmacological one now has to meld into a quieter world where drug therapy, which has had quite a battering in recent years and needs our support, will be joined by other approaches as equal partners, preferably working together in harness rather than in conflict.”

--Peter Tyrer, Editor

British Journal of Psychiatry, August 2012
**Societal Questions Re SSRIs**

1. If the short-term and long-term data reviewed here were incorporated into clinical care guidelines for treating depression, what would those guidelines recommend?

2. Is there any evidence to be found that shows that SSRIs have decreased the burden of mental illness in any society that has embraced the use of these drugs? Or does all of the available evidence show that the opposite is true?

3. What are the medical costs of patients in the five years before exposure to an SSRI, compared to the five years after exposure?
4. What percentage of people who are prescribed an SSRI end up with a bipolar diagnosis?

5. What percentage of people who are prescribed an SSRI end up on disability in the next 10 years?

6. Is there a risk of early dementia with continual SSRI use?

7. Is there a risk of early mortality with continual SSRI use?
Alternatives

The Opportunity:

History and science are telling us that there is a natural capacity to recover from depression, and that even bipolar disorder runs an episodic course, with fairly good long-term outcomes.

The Challenge:

How do we provide therapies that assist that enhance that natural capacity to recovery?
Possibilities:

• Exercise
• Diet/nutrition
• Psychosocial therapies
• Etc.